KaydedilenlerDerginizi ekleyin

Dergiler / Annals of Medical Research / 2020 / Cilt: 27 - Sayı: 2

Increase in C-peptide levels after resolution of hyperglycemia in patients with type 2 diabetes mellitus: Myths or facts?

Bahri EVREN
İbrahim ŞAHİN
Ömercan TOPALOĞLU
Saim YOLOĞLU
Şelale ŞAHİN
Sayfa
648–656
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

There were no significantdifferences between subgroups (age, BMI, diabetes duration, use of secretagogue, diabetic ketaoacidosis history, HbA1c (

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aim: Long term control of glucotoxicity was shown to increase the secretion of insulin and C-peptide (Cp).
📊
Temel Bulgular & Veri:We aimed to investigatethe change in Cp levels after short term glycemic control in patients with uncontrolled type 2 diabetes mellitus (DM).Material and Methods: Patients with type 2 DM with uncontrolled hyperglycemia were included.
💡
Sonuç & Katkı:There were no significantdifferences between subgroups (age, BMI, diabetes duration, use of secretagogue, diabetic ketaoacidosis history, HbA1c (
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Aim: Long term control of glucotoxicity was shown to increase the secretion of insulin and C-peptide (Cp). We aimed to investigatethe change in Cp levels after short term glycemic control in patients with uncontrolled type 2 diabetes mellitus (DM).Material and Methods: Patients with type 2 DM with uncontrolled hyperglycemia were included. Basal fasting Cp levels weremeasured both at admission (Cp-admission) and after control of hyperglycemia prior to discharge (Cp-discharge). Cp-differencewas calculated as (Cp-discharge)-(Cp-admission). The patients were divided as group 1 (positive Cp-difference) and group 2(negative Cp-difference), and group A (Cp-difference ≥+0.5) and group B (Cp-difference ≤-0.5).Results: Of the patients (n=123), 61.8% had positive Cp-difference, and mean Cp-differences were 0.16 (±1.59), 0.96 (±1.03), and-1.11 (±1.51) in all patients, group1 and 2; respectively (p=0.001). Mean body weight, creatinine and Cp-discharge were higher ingroup 1(p=0.045, p=0.013, p=0.001; respectively). Mean age, body mass index(BMI), diabetes duration, hospitalization, proteinuria,fasting and postprandial glucose, glucose-discharge, HbA1c, lipids, TSH, free T4, Cp-admission were similar in group 1 and 2.Cpdifference was correlated positively with Cp-discharge(p=0.001), negatively with Cp-admission (p=0.001). There were no significantdifferences between subgroups (age, BMI, diabetes duration, use of secretagogue, diabetic ketaoacidosis history, HbA1c (

🔖

Bu Makaleye Atıf Yap

EVREN, B., ŞAHİN, İ., TOPALOĞLU, Ö., YOLOĞLU, S., ŞAHİN, Ş. (2022). Increase in C-peptide levels after resolution of hyperglycemia in patients with type 2 diabetes mellitus: Myths or facts?. Annals of Medical Research, Cilt: 27 - Sayı: 2, 648–656. https://ajindex.com/articles/446487

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Forst T, Kunt T, Pohlmann T, et al. Biological activity of C-peptide on the skin microcirculation in patients with insulin-dependent diabetes mellitus. J Clin Invest 1998;101:2036-41
  2. Nakamura H, Jinzu H, Nagao K, et al. Plasma amino acid profiles are associated with insulin, C-peptide and adiponectin levels in type 2 diabetic patients. Nutr Diabetes;1:4:e133
  3. Lappas M, Jinks D, Ugoni A, et al. Postpartum plasma C-peptide and ghrelin concentrations are predictive of type 2 diabetes in women with previous gestational diabetes mellitus. J Diabetes 2014
  4. Pipi E, Marketou M, Tsirogianni A. Distinct clinical and laboratory characteristics of latent autoimmune diabetes in adults in relation to type 1 and type 2 diabetes mellitus. World J Diabetes 2014;5:505-10
  5. Tabák AG, Jokela M, Akbaraly TN, et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009;373:2215-21
  6. Kosaka K, Akanuma Y. Heterogeneity of plasma IRI responses in patients with IGT. Diabetologia 1980;18:347-48
  7. Kadowaki T, Miyake Y, Hagura R, et al. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia 1984;26:44-9
  8. U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-5
  9. Sakuraba H, Mizukami H, Yagihashi N, et al. Reduced beta-cell mass and expression of oxidative stressrelated DNA damage in the islet of Japanese Type II diabetic patients. Diabetologia 2002;45:85-96
  10. Butler AE, Janson J, Bonner-Weir S, et al.β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102-10
  11. Lorenzo A, Razzaboni B, Weir GC, et al. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 1994;368:756-60
  12. Clark A, Cooper GJ, Lewis CE, et al. Islet amyloid formed from diabetes-associated peptide may be pathogenic in type-2 diabetes. Lancet 1987;2:231-4
  13. Eizirik DL, Korbutt GS, Hellerström C. Prolonged exposure of human pancreatic islets to high glucose concentrations in vitro impairs the beta-cell function. J Clin Invest 1992;90:1263-12
  14. Marshak S, Leibowitz G, Bertuzzi F, et al. Impaired beta-cell functions induced by chronic exposure of cultured human pancreatic islets to high glucose. Diabetes 1999;48:1230-6
  15. Maedler K, Spinas GA, Lehma